Treatment strategies for severe Henoch-Schönlein Purpura in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates treatment strategies for children aged 2-16 years with IgA vasculitis and severe gastrointestinal involvement. It is a multi-center, randomized, controlled prospective study conducted in three children's medical centers in Shanghai. Participants will be divided into two groups receiving either methylprednisolone or intravenous immunoglobulin (IVIG) to evaluate the cost-effectiveness and clinical outcomes of each treatment approach. The study aims to establish a feasible strategy for managing severe abdominal manifestations of this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. both genders
2. age between 2-16 years old
3. IgA vasculitis with gastrointestinal involvement
4. course of disease less than 2 months
5. refractory to ordinary dosage of prednisolone (less than 2mg/kg/d）

Exclusion Criteria:

1. patients with severe sepsis
2. patients with central nervous system infection,
3. patients with severe pneumonia
4. patients with chronic infection (such as EBV, CMV, Tuberculosis)
5. patients complicated by CKD who need renal replacement therapy
6. patients suffering from severe central nervous system complications as intracranial hemorrhage or neuropathy

Where it's running

• Children's Hospital of Fudan University
  Shanghai, China Recruiting
• Children's Hospital of Shanghai
  Shanghai, China Not yet recruiting
• Shanghai Children's Medical Centre
  Shanghai, China Not yet recruiting

Study contacts

• Principal investigator: Li Sun, MD — Children's Hospital of Fudan University
• Study coordinator: Li Sun, MD
• Email: lillysun@263.com
• Phone: +8618017590930

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Mycophenolate Mofetil for Gastrointestinal Issues in Children with Henoch-Schönlein Purpura

  This study tests if a medication called Mycophenolate Mofetil can help children aged 3 to 18 with stubborn stomach problems caused by Henoch-Schönlein Purpura when other treatments haven't worked.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT05951517

• Comparing treatments for isolated skin vasculitis

  This study is testing which of three common treatments—colchicine, dapsone, or azathioprine—works best for people with isolated skin vasculitis over a year.

  Recruiting at 7 sites Phase 2 University of Pennsylvania · Kansas City, Kansas and 15 other locations · NCT02939573

• Personalized IgA Nephropathy treatment guided by Gd-IgA1 monitoring

  This study tests whether regularly checking a biomarker called Gd-IgA1 to guide treatment with Nefecon or telitacicept helps people with IgA nephropathy or related nephritis respond better.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07822100

• Finerenone treatment for children with Henoch–Schönlein purpura nephritis and mild proteinuria

  This trial will test whether adding finerenone to standard ACEI/ARB therapy helps reduce protein in the urine and is safe for children aged 3 to 17 with HSPN and mild proteinuria.

  Recruiting Phase 4 Capital Institute of Pediatrics, China · Beijing, Beijing Municipality · NCT07315191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.